Cargando…

Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study

AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the gluta...

Descripción completa

Detalles Bibliográficos
Autores principales: Vingerhoets, Claudia, Tse, Desmond HY, van Oudenaren, Mathilde, Hernaus, Dennis, van Duin, Esther, Zinkstok, Janneke, Ramaekers, Johannes G, Jansen, Jacobus FA, McAlonan, Grainne, van Amelsvoort, Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376622/
https://www.ncbi.nlm.nih.gov/pubmed/32448020
http://dx.doi.org/10.1177/0269881120922977
_version_ 1783562072699699200
author Vingerhoets, Claudia
Tse, Desmond HY
van Oudenaren, Mathilde
Hernaus, Dennis
van Duin, Esther
Zinkstok, Janneke
Ramaekers, Johannes G
Jansen, Jacobus FA
McAlonan, Grainne
van Amelsvoort, Therese
author_facet Vingerhoets, Claudia
Tse, Desmond HY
van Oudenaren, Mathilde
Hernaus, Dennis
van Duin, Esther
Zinkstok, Janneke
Ramaekers, Johannes G
Jansen, Jacobus FA
McAlonan, Grainne
van Amelsvoort, Therese
author_sort Vingerhoets, Claudia
collection PubMed
description AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge. METHODS: Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined. RESULTS: No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC (η(2) = 0.094) but not striatal glutamate concentrations as well as ACC GABA concentrations (η(2) = 0.176) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients. DISCUSSION: We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition.
format Online
Article
Text
id pubmed-7376622
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73766222020-08-13 Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study Vingerhoets, Claudia Tse, Desmond HY van Oudenaren, Mathilde Hernaus, Dennis van Duin, Esther Zinkstok, Janneke Ramaekers, Johannes G Jansen, Jacobus FA McAlonan, Grainne van Amelsvoort, Therese J Psychopharmacol Original Papers AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge. METHODS: Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined. RESULTS: No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC (η(2) = 0.094) but not striatal glutamate concentrations as well as ACC GABA concentrations (η(2) = 0.176) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients. DISCUSSION: We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition. SAGE Publications 2020-05-25 2020-08 /pmc/articles/PMC7376622/ /pubmed/32448020 http://dx.doi.org/10.1177/0269881120922977 Text en © The Author(s) 2020 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Vingerhoets, Claudia
Tse, Desmond HY
van Oudenaren, Mathilde
Hernaus, Dennis
van Duin, Esther
Zinkstok, Janneke
Ramaekers, Johannes G
Jansen, Jacobus FA
McAlonan, Grainne
van Amelsvoort, Therese
Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title_full Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title_fullStr Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title_full_unstemmed Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title_short Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
title_sort glutamatergic and gabaergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: a randomized double-blind 7-tesla pharmacological mrs study
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376622/
https://www.ncbi.nlm.nih.gov/pubmed/32448020
http://dx.doi.org/10.1177/0269881120922977
work_keys_str_mv AT vingerhoetsclaudia glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT tsedesmondhy glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT vanoudenarenmathilde glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT hernausdennis glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT vanduinesther glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT zinkstokjanneke glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT ramaekersjohannesg glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT jansenjacobusfa glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT mcalonangrainne glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy
AT vanamelsvoorttherese glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy